Diabetic Gastroparesis Treatment Global Market Report 2023 – By Treatment (Medication, Surgery), By Route Of Administration (Oral, Injectables), By Indication (Compensated Gastroparesis, Gastric Failure), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels), By End User (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2023-2032

Diabetic foot ulcer refers to skin soreness with full-thickness skin loss on the foot due to neuropathic and vascular complications in patients suffering from diabetes mellitus, which slowdowns the healing process of sores and makes it prone to infection. Diabetic foot ulcer treatment is used to prevent, treat, and manage foot ulcers caused in diabetic patients to avoid amputation if neglected. The main types of diabetic foot ulcer treatment are wound care dressings, biologics, therapy devices, antibiotic medications, and other treatments. Wound care dressings refer to a sterile pad that is used to cover wounds to promote healing and protect them from further damage. Wound care dressings are used to protect wounds to encourage a faster healing process. The main types of ulcer are neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcer categorised as grade 1, grade 2, grade 3, grade 4, grade 5. The diabetic foot ulcer treatment is used by hospital, ambulatory surgery centre, and other end-users. The global diabetic foot ulcer treatment market is segmented - 1) By Treatment: Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications, Other Treatments 2) By Ulcer Type: Neuropathic Ulcers, Ischemic Ulcers, Neuro-Ischemic Ulcers 3) By Grade: Grade 1, Grade 2, Grade 3, Grade 4, Grade 5 4) By End-User: Hospital, Ambulatory Surgery Centre, Other End-Users The global diabetic foot ulcer treatment market size is expected to grow from $6.43 billion in 2022 to $6.93 billion in 2023 at a compound annual growth rate (CAGR) of 7.76%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the diabetic foot ulcer treatment market is expected to reach $9.41 billion in 2027 at a CAGR of 7.93%. The increased number of diabetes patients is expected to propel the growth of the diabetic foot ulcer treatment market going forward. Diabetes is a metabolic illness with a long-term course that causes elevated blood glucose levels and, over time, causes substantial harm to the heart, blood vessels, eyes, kidneys, and nerves. Diabetes is the leading cause of foot ulcers, leading to an increased demand for diabetic foot ulcer treatment. For instance, in 2022, according to Centers for Disease Control and Prevention, a US-based national public health agency, around 37.3 million people are suffering from diabetes which equals 11.3% of the United States population. Additionally, in December 2021, according to the International Diabetes Federation, a Belgium-based leading global diabetes community approximately 537 million adults are suffering from diabetes globally, whereas 3 out of 4 adults are in low- and middle-income countries. Therefore, the increased number of diabetes patients is driving the growth of the diabetic foot ulcer treatment market. Major players in the diabetic foot ulcer treatment market are Coloplast A/S, Medtronic PLC., Molnlycke Health Care AB, B. Braun Melsungen AG, Medline Industries Inc., BSN Medical GMBH, Molnlycke Health Care AB, Acelity L.P. Inc., Organogenesis Inc., 3M Healthcare, Smith & Nephew PLC., ConvaTec Inc., Oneness Biotech Co. Ltd., Dipexium Pharmaceuticals Inc., ViroMed Co. Ltd., and FirstString Research Inc. Technological advancement is a key trend in the diabetic foot ulcer treatment market. Major market players are focusing on innovative technologies such as cloud-based AI technology for the detection of diabetic foot ulcers. For instance, in October 2021, Manchester Metropolitan University, a UK-based research university technology company, partnered with Oracle Corporation, a US-based multinational computer technology, and database management company, and introduced healthcare technology for diabetic foot problems known as FootSnap AI. FootSnap AI uses a mobile application that uses deep learning technologies to accurately detect ulcers on photos of a patient's feet with high sensitivity (0.934) and specificity (0.911) in identifying images. In October 2021, Bioventus Inc., a US-based company operating in active wound healing, acquired MISONIX Inc for an undisclosed amount. Through this acquisition, Bioventus Inc. aims to strengthen its product portfolio in diabetic foot ulcer treatment and its active healing position. MISONIX Inc. is a US-based company operating in ultrasonic surgical devices and diabetes foot ulcer treatment. North America was the largest region in the diabetic foot ulcer treatment market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic foot ulcer treatment market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the Diabetic Foot Ulcer Treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and the USA. The diabetic foot ulcer treatment market includes revenues earned by entities by ultrasound therapy, negative pressure wound therapy, and active therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The diabetic foot ulcer treatment market research report is one of a series of new reports from The Business Research Company that provides diabetic foot ulcer treatment market statistics, including diabetic foot ulcer treatment industry global market size, regional shares, competitors with a diabetic foot ulcer treatment market share, detailed diabetic foot ulcer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic foot ulcer treatment industry. This diabetic foot ulcer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetic neuropathy is a type of nerve damage that can occur in people with diabetes. High blood sugar levels induce it, which can damage the blood vessels. It can harm various nerves in the body, including those in the feet, organs, and muscles. The main disorders of diabetic neuropathy are peripheral neuropathy, autonomic neuropathy, proximal neuropathy and focal neuropathy. Peripheral neuropathy is a disorder that occurs when the peripheral nerves, which carry information to and from the brain and spinal cord to the rest of the body, are damaged. The various classes of drugs used for diabetic neuropathy are analgesics, anti-depressants, anti-convulsants, and others, that involve drug treatment, radiotherapy, physiotherapy, and others. These are provided through several distribution channels, such as online distribution and offline distribution, which are used in hospitals, specialty clinics and others. The global diabetic neuropathy market is segmented - 1) By Disorder: Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy 2) By Drug Class: Analgesics, Anti-Depressants, Anti-consulvants, Other Drug Classes 3) By Treatment: Drug Treatment, Radiotherapy, Physiotherapy, Other Treatments 4) By Distribution Channel: Online Distribution, Offline Distribution 5) By End-user: Hospitals, Specialty Clinics, Other End-users The global diabetic neuropathy market size is expected to grow from $4.52 billion in 2022 to $4.97 billion in 2023 at a compound annual growth rate (CAGR) of 9.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global diabetic neuropathy market size is expected to reach $6.90 billion in 2027 at a CAGR of 8.5%. The rising prevalence of diabetes is expected to boost the growth of the diabetic neuropathy market going forward. Diabetes is a persistent disorder where the body struggles to use and store glucose appropriately (a type of sugar). Diabetes occurs when the body either does not create enough insulin (a hormone that aids in blood sugar regulation) or does not use insulin effectively. Diabetic neuropathy is a type of nerve injury that can occur in diabetics with d different forms of nerve damage causing different symptoms. For instance, in August 2022, according to the IDF Diabetes Atlas report published by the International Diabetes Federation, a Belgium-based global diabetes community and an umbrella organization of over 230 national diabetes associations, 6.7 million deaths were attributed to diabetes in the year 2021, which is equivalent to one death every five seconds. There are currently 537 million adults (aged 20–79) living with diabetes, or 1 in 10 people. It is estimated that this number will increase to 643 million by 2030 and 783 million by 2045. Therefore, the rising prevalence of diabetes is driving the growth of the diabetic neuropathy market. Major players in the diabetic neuropathy market are Pfizer Inc., Eli Lilly and Company, GSK PLC (GlaxoSmithKline PLC), Daiichi Sankyo Company Limited, Johnson & Johnson, Glenmark Pharmaceuticals Limited, Depomed Inc., Astellas Pharma Inc., F. Hoffmann-La Roche AG, NeuroMetrix Inc., Abbott Laboratories, Lupin Limited, Novartis AG, Boehringer Ingelheim, and Janssen Pharmaceuticals Inc. Technological advancements have emerged as a key trend gaining popularity in the diabetic neuropathy market. Major companies operating in the diabetic neuropathy market are focused on providing innovative solutions to strengthen their position in the market. For instance, in July 2021, Nevro Corporation, a US-based medical device company, developed Senza (also known as "HFX"), a high spinal cord stimulation technology for the treatment of painful diabetic neuropathy (PDN), a condition that affects up to one-third of people with diabetes (PWDs) in the United States and causes loss of sensation and pain in the lower limbs. Senza® HFX iQTM is the next generation technology that uses artificial intelligence to optimise and maintain pain alleviation based on each patient's response. It was designed to take into consideration how different people experience pain and to help patients achieve and maintain long-term pain relief and an improved quality of life. The Senza HFX iQ system, which includes the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, will be the first to use algorithms built specifically for treating chronic back and leg pain, such as severe diabetic neuropathy and non-surgical back pain. In January 2022, Withings SA, a France-based consumer electronics company that designs, and manufactures a range of clinically validated smart health devices and associated apps, acquired Impeto Medical SAS for an undisclosed amount. This acquisition enables Withings to incorporate Impeto’s technologies, including nerve tracking activity, into its products and services. Impeto Medical SAS is a France-based medical device company that manufactures tools for monitoring peripheral neuropathies to detect small fiber neuropathies in a variety of diseases and conditions. North America was the largest region in the diabetic neuropathy market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global diabetic neuropathy market during the forecast period. The regions covered in the global diabetic neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the diabetic neuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The diabetic neuropathy market consists of sales of drugs such as anticonvulsants, pain medications, nerve growth factor inhibitors and other drugs that are used to treat the symptoms of nerve damage caused by diabetes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The diabetic neuropathy market research report is one of a series of new reports from The Business Research Company that provides diabetic neuropathy market statistics, including diabetic neuropathy industry global market size, regional shares, competitors with a diabetic neuropathy market share, detailed diabetic neuropathy market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic neuropathy industry. This diabetic neuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetic kidney disease refers to a type of renal disease driven by complications of diabetes that occurs when high levels of blood sugar cause damage to the kidneys. The blood vessels in the kidneys can become affected by high blood glucose, which ultimately reduces their functionality. The main types of diabetic kidney disease are type 1 diabetes and type 2 diabetes. Type 1 diabetes refers to a chronic autoimmune condition in which the pancreas produces little or no insulin, leading to high blood sugar levels that cause harm to the nephrons and renal blood vessels and requiring daily insulin injections to manage blood sugar levels. They are treated by angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, antioxidant inflammation modulators, calcium channel blockers, and other treatments in medical facilities including hospitals, homecare, specialty centers, and others. The global diabetic kidney disease market is segmented - 1) By Type: Type 1 Diabetes, Type 2 Diabetes 2) By Treatment: Angiotensin Receptor Blockers (Arbs), Angiotensin-Converting Enzyme (Ace) Inhibitors, Antioxidant Inflammation Modulator, Calcium Channel Blockers, Other Treatments 3) By End User: Hospitals, Homecare, Speciality Centres, Other End Users The global diabetic kidney disease market size is expected to grow from $2.37 billion in 2022 to $2.51 billion in 2023 at a compound annual growth rate (CAGR) of 5.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global diabetic kidney disease market size is expected to reach $3.09 billion in 2027 at a CAGR of 5.4%. The rising prevalence of chronic kidney disease is expected to propel the growth of the diabetic kidney disease market. Chronic kidney disease (CKD) refers to a long-term condition that results in the loss of kidney function over time causing a number of complications such as high blood pressure, anemia, and bone diseases. The treatment of chronic kidney diseases requires diagnostic and treatment options, ultimately fueling the growth of the diabetic kidney disease market. For instance, in 2021, according to the report published by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, more than 37 million people were estimated to have chronic kidney disease (CKD) in the USA. Furthermore, CKD is more common in adults 65 and older, with approximately 38% of older adults suffering from some form of kidney damage. Therefore, the rising prevalence of chronic kidney disease is driving the growth of the diabetic kidney disease market going forward. Major players in the diabetic kidney disease market are AstraZeneca, Pfizer Inc., Novartis AG, Bayer AG, Sanofi Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Mylan NV, Aurobindo Pharma, Fresenius SE & Co. KGaA, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Reata Pharmaceuticals, and Merck & Co. Technological advancements are a key trend gaining popularity in the diabetic kidney disease market. Companies operating in the diabetic kidney disease market are adopting new technologies to sustain their position in the market. For instance, in August 2022, Bloom Diagnostics, a US-based diagnostics and healthcare devices organization, launched the Bloom Kidney Test, a new tool that can be integrated with the Bloom Smart System. The Bloom Kidney Test is a diagnostic tool that assesses kidney health by measuring cystatin C levels, which is a reliable indicator of kidney function. It classifies kidney function into three categories: normal, mildly decreased, and decreased. The Bloom Smart System leverages cloud-based algorithms and AI (artificial intelligence) technology to integrate test results with other relevant health information, such as medical history, lifestyle, and symptoms of the patient. In January 2023, AstraZeneca, a UK-based biotechnology, and pharmaceutical company, acquired Cincor Pharma Inc, for an undisclosed amount. This acquisition will bolster AstraZeneca’s cardiorenal pipeline by adding CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension. CinCor Pharma Inc. is a US-based biopharmaceutical company specializing in the development of drugs for the management of kidney disease. North America was the largest region in the diabetic kidney disease market in 2022. The regions covered in the global diabetic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the diabetic kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The diabetic kidney disease market includes revenues earned by entities by providing diabetic kidney disease treatments for kidney stones, kidney infection, polycystic kidney disease, and kidney cysts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The diabetic kidney disease market research report is one of a series of new reports from The Business Research Company that provides diabetic kidney disease market statistics, including global market size, regional shares, competitors with a diabetic kidney disease market share, detailed diabetic kidney disease market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic kidney disease industry. This diabetic kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetic foods are dietary products with low carbohydrate and sugar content that aid in blood glucose regulation. The main product types are bakery products, dairy products, confectionery products, beverages, snacks, and others. A dairy product is milk and any of foods made from milk, including butter, cheese, ice cream, yogurt, and condensed and dried milk. The distribution channels for diabetic foods are supermarkets and hypermarkets, drug stores, pharmacies, online stores, and others. The various end users are children and adults. The global diabetic foods market is segmented - 1) By Product Type: Bakery Products, Dairy Products, Confectionery Products, Beverages, Snacks, Other Product Types 2) By Distribution Channel: Supermarkets and Hypermarkets, Drug Stores/Pharmacies, Online Stores, Other Distribution Channels 3) By End User: Children, Adults The global diabetic foods market size will grow from $11.57 billion in 2022 to $13.26 billion in 2023 at a compound annual growth rate (CAGR) of 14.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global diabetic foods is expected to grow from $21.7 billion in 2027 at a CAGR of 13.1%. Increasing cases of juvenile diabetes among children and youth is a key factor driving the growth of the diabetic foods market. Incidences of diabetes are growing all over the world, and therefore diabetes among children is quite common. Most children have type 1(juvenile) diabetes during childhood. About 90% of young people with diabetes suffer from Type 1. For people with type 1 diabetes, the Mediterranean diet plan is recommended because it is full of nutrient-dense foods, including plenty of fresh vegetables, some oranges, plant fats such as olive oil and nuts, fish such as sardines, and occasional meat and milk. According to the Centers for Disease Control and Prevention [CDC], 2020, more than 34 million Americans have diabetes, which is nearly 11% of the U.S. population and 1.6 million Americans have Type 1 diabetes, which includes 187,000 children and adolescents. Therefore, the increasing number of cases of juvenile diabetes among children and youth is expected to drive the growth of the diabetic foods market. Major players in the diabetic foods market are David Chapman's Ice Cream Ltd., Fifty 50 Food Inc., Nestlé SA, Unilever PLC., Mars Incorporated, The Coca-Cola Company, PepsiCo Inc., Kellogg Co., Cadbury PLC., Zen Health Japan Co. Ltd. Food labelling is a key factor hindering the growth of the diabetic foods market. There has been a concern for some time that labelling food as "diabetic" could confuse people with diabetes into believing that food is important or at least especially necessary. Improvement in food policy ensures that companies will not be able to label food as "diabetic" or "made for diabetics". Diabetes UK reacted furiously and has been fighting for the removal of the labels for over 30 years, which wrongly suggest a health advantage for people with diabetes and are seen as important to conventional alternatives. Therefore, labelling food is expected to restrict the growth of the diabetic foods market. Product innovation is the key trend in the diabetic foods market. The introduction of various items such as low-calorie sweet beverages, sugar-free jellies, diabetic bakery items, low-fat ice cream, and other dairy goods is attracting more customers towards the diabetic foods market. For instance, companies like Coke, Pepsi, Thumps Up and Sprite introduced new beverages such as protein shakes, good-for-good beverages, and functional waters that are gradually making their presence felt in retail stores and contributing to faster growth in the overall beverage category. With an annual growth rate of 7%, the carbonated soft drinks (CSD) industry in India is pegged at Rs 25,000. Coke's biggest segment in the US, Diet Coke, and Coke Zero Sugar, contributed to an 8% rise in retail sales growth last year for the brand of non-calorie sparkling soft drinks. It reported a 5% organic global growth overall for the year. In April 2022, Kerry Group PLC., an Ireland-based nutrition company acquired Natreon, Inc. for an undisclosed amount. Through this acquisition, Kerry Group plc aims to strengthen its product portfolio in nutrient solutions and expand its research capabilities. Natreon, Inc. is a US-based company operating in ayurvedic botanical ingredients. Asia-Pacific was the largest region in the diabetic foods market in 2022. Western Europe was the second-largest region in the diabetic foods market report. The regions covered in the diabetic foods industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the diabetic foods market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The diabetic foods market consists of sales of low-calorie sweeteners, diet beverages, and other diabetic foods. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The diabetic foods research report is one of a series of new reports from The Business Research Company that provides diabetic foods statistic, including diabetic foods industry global market size, regional shares, competitors with diabetic foods share, detailed diabetic foods segments, market trends, and opportunities, and any further data you may need to thrive in the diabetic foods industry. The diabetic foods research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Ocular implants are used to improve eye vision of a person. These implants help improve the fixing sight of people who have lost an eye to injury or disease, commonly called a glass eye, made up of hard plastic acrylic. The prosthetic eye has a shell form, consisting of a clear, artificial lens implant, used to replace a cloudy natural lens in cataract surgery. The main types of products in ocular implants are intraocular lens, corneal implants, orbital implants, glaucoma implants and others. The intraocular lens are made from chemicals or artificial substances such as clear plastic, silicone, or acrylic. It bends (refracts) light rays that enter the eye, helping one to see. They are coated with a special material that can help to protect your eyes from the harmful ultraviolet rays emitted by the sun. These ocular implants are used in glaucoma surgery, diabetic retinopathy and age-related macular degeneration by end-user such as specialty eye institutes, hospitals and clinics. The global ocular implants market is segmented - 1) By Product: Intraocular Lens, Corneal Implants, Orbital Implants, Glaucoma Implants, Other Products 2) By Application: Glaucoma Surgery, Diabetic Retinopathy, Age-Related Macular Degeneration 3) By End-User: Specialty Eye Institutes, Hospitals, Clinics The global ocular implants market size grew from $12.03 billion in 2022 to $12.98 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the ocular implants market is expected to grow to $17.66 billion in 2027 at a CAGR of 8.0%. The increase in prevalence of eye disorders across the world is going to be a major driver in the growth of the ocular implants market. The foremost common eye disorders within the U.S. Isis refractive errors. For instance, in 2022 in line with American Academy of Ophthalmology (AAO) offer statistics on the prevalence of visual defect because of eye disorders by ethnicity yet because the breakdown of individuals who are legally blind thanks to eye diseases or eye disorders by grouping. Within the united statesUnited States alone, about 12 million people ageaged 40 and above suffer from vision impairment, with about a million full of blindness globally, the similar reports about 2.2 billion individuals have eye and visual disorders, according to the world health organization. Hence, the rising prevention of eye disorders, is anticipated more demand for ocular implants increasing prevalence of eye disorders like cataract and glaucoma is to fuel the demand for ocular implants. Major players in the ocular implants market are Alcon Inc., Bausch & Lomb Inc., Carl Zeiss AG, ZEISS International, STAAR Surgical Company, Morcher GmbH, Hoya Corporation, and Glaukos Corporation. Technological advancements and innovations has been a key trend gaining popularity in the ocular implants market. Technological advancements are the discovery of knowledge that helps in developing products using advanced technology. Major companies operating in the ocular implants market are focused on developing new technological solutions to meet customer demand and make ocular implants more advanced. For instance, In July 2021, ZEISS, a Germany-based manufacturer of optical systems and optoelectronics, introduced the ZEISS Medical Ecosystem. The ZEISS Medical Ecosystem is an entirely integrated setting that uses various tools for data management, apps, and services to enhance patient outcomes continuously. This ecosystem's unique combination of unmatched ocular knowledge and cutting-edge digital technology makes it possible to make decisions based on the best available data, ensuring the most effective treatment delivery on a single, secure platform. in 2019 France based bioelectronics and brain-machine interface technology company PIXIUM VISION recently introduced PRIMA System artificial eye technology that partially replaces the normal physiological functioning of the photoreceptors of the eye, with a mini camera mounted on the glasses that captures visual scenes in the environment, which gets processed and simplified by the pocket computer, in order to extract meaningful information from the photos, using artificial intelligence breakthrough algorithms. In patients, 36 months after implantation, the PRIMA implant was well tolerated and safe. These observations are in line with Vitro reliability studies that showed the implants to be 100% reliable with the pixels reliability of over 90%, for over the past 20 years. In August 2021, Alcon, a Switzerland-based medical company offering dedicated eye care, announced acquisition of Ivantis®, $475 million in cash up front. The aim of this acquisition demonstrates Alcon's commitment to the surgical glaucoma market, bolstering the company's industry-leading portfolio in cataract, refractive, retina, and glaucoma. Ivantis® is a US-based company the developing and manufacturing the Hydrus® Microstent, a novel minimally invasive glaucoma surgery (MIGS) device the designed to lower intraocular pressure in open-angle glaucoma patients during cataract surgery. North America was the largest region in the ocular implants market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ocular implants market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the ocular implants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The ocular implants market consists of sales ofmonofocal lens, toric lens, multifocal and accommodating lenses. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The ocular implants market research report is one of a series of new reports from The Business Research Company that provides ocular implants market statistics, including ocular implants industry global market size, regional shares, competitors with a ocular implants market share, detailed ocular implants market segments, market trends and opportunities, and any further data you may need to thrive in the ocular implants industry. This ocular implants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Wound debridement refers to the procedure of treating a wound in the skin by removing the dead skin from the wound. The debridement procedure helps in healthy tissue growth, minimizes scarring, and reduces the chances of infection. Depending on the wound, the type of debridement is selected on top of the form. Debridement can be done surgically or using non-surgical procedures such as the use of specific dressings and gels. The wound debridement helps to remove all the devitalized tissue from the wound bed and aid in faster wound healing. The main types of wound debridement are enzymatic debridement products, autolytic debridement products, gels, ointments, mechanical debridement products, ultrasonic debridement products, and others. Enzymatic wound debridement refers to the wound debridement method that uses highly selective natural occurring proteolytic enzymes manufactured by the industry. Enzymatic debridement products are used in removing necrotic material from partial-thickness wounds, pressure ulcers, and leg ulcers. The various wound types include venous leg ulcers, diabetic foot ulcers, pressure ulcers, surgical and traumatic wounds, burns, and others that are treated using several methods such as the surgical method, enzymatic method, mechanical method, autolytic method, and other methods. The several end-users include hospitals, clinics, and others. The global wound debridement market is segmented - 1) By Product: Enzymatic Debridement Products, Autolytic Debridement Products, Gels, Ointments, Mechanical Debridement Products, Ultrasonic Debridement Products, Other Products 2) By Method: Surgical Method, Enzymatic Method, Mechanical Method, Autolytic Method, Other Methods 3) By Wound Type: Venous Leg Ulcers, Diabetic Foot Ulcers, Pressure Ulcers, Surgical and Traumatic Wounds, Other Wound Types 4) By End User: Hospitals, Clinics, Other End Users The global wound debridement market size grew from $4.64 billion in 2022 to $5.04 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global wound debridement is expected to grow to $6.36 billion in 2027 at a CAGR of 6.0%. Growing awareness programs for wound care and management are expected to propel the growth of the wound debridement market going forward. There are various causes of wounds such as injury, accident, surgical wounds and burns, diabetes, vascular disease, and some chronic wounds, including leg ulcers, diabetic foot ulcers (DFUs), and pressure ulcers. Many wound management and prevention programs have been organized to create awareness about the severity of the wound. For instance, in June 2021, Healogics, a US-based company providing wound care services, launched the Healogics Wound Care Awareness Campaign from June 7–11, 2021, for a week to create awareness regarding the chronic wound healing program. This program is designed to help both patients and healthcare providers with resources and help improve health, heal wounds and prevent amputations. Many workshops have been arranged to create awareness about the wound’s severity and care. Therefore, the growing awareness programs for wound care and management are driving the growth of the wound debridement market. Major players in the wound debridement market are Smith & Nephew, B. Braun Melsungen AG, Coloplast, ConvaTec, Lohmann & Rauscher, Integra Lifesciences, Arobella Medical LLC, Medline Industries, Acelity L.P. Inc., DeRoyal Industries, Histologics LLC, ArthoCare Corporation, Advanced Medical Solutions Group, Söring GmbH, Bactiguard AB, Zimmer Biomet, Monarch Labs, Lohmann & Rauscher International GmbH & Co. KG (L&R Group), Mölnlycke Healthcare, Advancis Medical, RLS Global, Sanara MedTech Inc., and EZ Debride. Technological innovations are a key trend gaining popularity in the wound debridement market. Major market players are concentrating their efforts on creating innovative technologies for wound debridement. Wound care has come a long way in recent years, with wearable technologies, electronic health data, and a diverse range of devices for examination and dressings alone. For example, in June 2021, researchers from RMIT University, an Australian-based university, developed a new type of nanosensor with a glowing feature wound dressing unit for advanced care to track and monitor infection. The antibacterial and anti-inflammatory properties of magnesium hydroxide have been harnessed in this unit, which aids in the reduction of inflammation, the struggle against germs, and the faster healing of wounds. In December 2021, Essity AB, a Sweden-based company that manufactures wound debridement products, acquired Hydrofera for a deal amount of USD 116 million. With this acquisition, Essity's strategic priority is to expand in medical solutions and offer advanced wound care, as well as strengthen its innovation capability and expand in this industry. Hydrofera is a US-based company that manufactures wound debridement products. North America was the largest region in the wound debridement market in 2022. Asia-Pacific is expected to be the fastest-growing region in the wound debridement market report during the forecast period. The regions covered in the wound debridement industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the wound debridement market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The wound debridement market consists of sales of surgical debridement, enzymatic debridement, autolytic, and biological. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The wound debridement market research report is one of a series of new reports from The Business Research Company that provides wound debridement market statistics, including wound debridement industry global market size, regional shares, competitors with a wound debridement market share, detailed wound debridement market segments, market trends and opportunities, and any further data you may need to thrive in the wound debridement industry. This wound debridement market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetic retinopathy is an eye condition that can lead to blindness and vision loss in people with diabetes, affecting blood vessels in the retina and the light-sensitive tissue layer in the back of the eye. It commonly causes diabetic macular edema (DME) and neovascular glaucoma. The main diabetic retinopathy types are proliferative diabetic retinopathy, and non-proliferative diabetic retinopathy. Proliferative diabetic retinopathy refers to the advanced stage in which aberrant new blood vessels develop on the retina's surface. The various treatment methods are anti-vegf drugs, intraocular steroid injection, laser photocoagulation, and vitreoretinal surgery used in hospitals, ambulatory surgical centers, and others. The global diabetic retinopathy market is segmented - 1) By Type: Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy 2) By Treatment: Anti-VEGF Drugs, Intraocular Steroid Injection, Laser Photocoagulation, Vitreoretinal Surgery 3) By End-User: Hospitals, Ambulatory Surgical Centers, Other End Users The global diabetic retinopathy market is expected to grow from $7.25 billion in 2022 to $7.89 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The diabetic retinopathy market is expected to reach $10.57 billion in 2027 at a CAGR of 7.6%. The rising prevalence of diabetes is expected to propel the growth of the diabetic retinopathy market going forward. Diabetes refers to a long-term metabolic disease that causes high blood glucose levels. The rise in the prevalence of diabetes is mainly driven by overweight, obesity, genetics, and physical inactivity, whereas patients with diabetes have too much sugar in their blood, which can damage the retina, which is part of the eye that detects light and sends signals to your brain through a nerve in the back of eye. For instance, in November 2021, according to the International Diabetes Federation, a Belgium-based diabetes federation, the prevalence of diabetes was 10.5% worldwide in 2021, with over half (44.7%) of people still undiagnosed. Further, the diabetic population is expected to increase from 643 million (11.3%) by 2030 to 783 million (12.2%) by 2045. Therefore, the rising prevalence of diabetes is driving the growth of the diabetic retinopathy market. Major players in the diabetic retinopathy market are Pfizer Inc., F-Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Ellex Medical Lasers Ltd., Abbott Laboratories Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Icon Bioscience Inc., Allergan plc., Genentech Inc., Aurobindo Pharma, Santen Pharmaceutical Co. Ltd., Carl Zeiss Meditec AG, Valeant Pharmaceuticals International Inc., Lumenis Ltd., Optos Plc., Quantel Medical SAS, NIDEK Co. Ltd., IRIDEX Corporation, Alimera Science Inc., Kowa Company Ltd., Ocular Therapeutix Inc., Aerpio Pharmaceuticals Inc., Kodiak Sciences Inc., Sirnaomics Inc., Oxurion NV, Graybug Vision Inc., and Ampio Pharmaceuticals Inc. Technological advancements are a key trend gaining popularity in the diabetic retinopathy market. Major companies operating in the large volume parenteral market are adopting new technologies to sustain their position in the market. For instance, in July 2022, Baxter International Inc., a US-based healthcare company, launched Welch Allyn RetinaVue 100 Imager PRO in South Korea. These technologies are intended to allow for the detection of diabetic retinopathy in primary care settings. RetinaVue has proven to increase patient compliance for potentially life-saving annual diabetic retinal exams (DREs) by screening patients quickly and comfortably during a routine primary care visit. In January 2022, Meteda, a US-based healthcare technology company, acquired Retmarker SA for an undisclosed amount. Through this acquisition, Meteda aims to expand its access to periodic screening for diabetic retinopathy, use AI to handle several diabetes issues, and strengthen its position in the EMEA region. Retmarker SA is a Portugal-based AI technology company focusing on ophthalmology, especially retinal conditions such as diabetic retinopathy. North America was the largest region in the diabetic retinopathy market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetic retinopathy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the diabetic retinopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The diabetic retinopathy market includes revenues earned by entities by providing ophthalmologic examination, eye management and retinal imaging and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The diabetic retinopathy market research report is one of a series of new reports from The Business Research Company that provides diabetic retinopathy market statistics, including diabetic retinopathy industry global market size, regional shares, competitors with a diabetic retinopathy market share, detailed diabetic retinopathy market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic retinopathy industry. This diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastroparesis is a medical condition characterized by the impairment or weakening of the stomach muscles, resulting in delayed emptying of stomach contents into the small intestine. Gastroparesis is treated by medications to stimulate stomach emptying and manage underlying conditions, and surgical interventions. The main treatment modalities of gastroparesis are medications, dietary modifications, medical devices, and others. Medications are substances that work by interacting with the body's biological processes to produce a desired effect. Medications such as prokinetic drugs, antiemetics, botulinum toxin injections, antidepressants, and others are used to diagnose, treat, cure, or prevent gastroparesis. These are used for the treatment of idiopathic, diabetic, post-surgical, and others in pediatric and adult patients. These are distributed by retail pharmacies, hospital pharmacies, and others, which are used by hospitals and clinics, ambulatory surgical centers, and home care settings. The global gastroparesis market is segmented - 1) By Treatment Modality: Medications, Dietary Modifications, Medical Devices, Other Therapies 2) By Gastroparesis Type: Idiopathic, Diabetic, Post- Surgical, Other Types 3) By Patient Demographics: Pediatric Gastroparesis, Adult Gastroparesis 4) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels 5) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Home Care Settings The global gastroparesis market is expected to grow from $6.08 billion in 2022 to $6.44 billion in 2023 at a compound annual growth rate (CAGR) of 5.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The gastroparesis market is expected to reach $7.77 billion in 2027 at a CAGR of 4.8%. The increasing prevalence of gastroparesis is expected to propel the growth of the gastroparesis market. Gastroparesis is a medical condition that stops or delays food movement from the stomach to the small intestine. Hypothyroidism, autoimmune diseases, injury to the vagus nerve, and viral stomach infections cause gastroparesis. Gastroparesis medicine tightens and contracts the muscles in the stomach wall and improves gastric emptying. For instance, in 2021, according to a research study published by Practice Update, a Netherlands-based online publisher of research articles, in 2021 the overall prevalence rate of gastroparesis was 267.7 per 100,000 persons in the US. The prevalence rate of definite gastroparesis was 21.5 per 100,000 persons. As a result, the increasing prevalence of gastroparesis is driving the growth of gastroparesis treatment. Major players in the gastroparesis market are Pfizer Inc., GlaxoSmithKline plc., Abbott Laboratories Inc., AstraZeneca Plc., Medtronic Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk AS, Johnson And Johnson Services Inc., Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boston Scientific Corporation, Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Daewoong Pharmaceutical co. ltd, ReGenXBio Inc., ANI Pharmaceuticals Inc., Dompe Farmaceutici S.p.A, Sucampo Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Orexo AB, Theravance Biopharma Inc., RQI Partners LLC., RedHill Biopharma Ltd., Synthorx Inc., Valeant Pharmaceuticals International Inc., CinRx Pharma LLC., Ritter Pharmaceuticals Inc., Evoke Pharma Inc., Metacrine Inc., and Neurogastrx Inc. The development of an advanced drug for the treatment of gastroparesis is a key trend gaining popularity in the gastroparesis market. Major companies operating in the gastroparesis market are developing innovative drug formulations to sustain their position in the market. For instance, in June 2020, Evoke Pharma, a US-based pharmaceuticals company, received approval for its metoclopramide nasal spray from the US Food and Drug Administration, a US-based health regulatory agency for treating gastroparesis. The new formulation is the first and only nasally administered medication for treating acute and recurrent diabetic gastroparesis. In May 2020, AbbVie Inc., a US-based pharmaceutical company, acquired Allergan plc for an undisclosed amount. The acquisition diversified AbbVie's presence in newer therapeutic areas and helped it reach a broader consumer base. Allergan plc is an Ireland-based pharmaceutical company that develops drugs for treating gastroparesis. North America was the largest region in the gastroparesis market in 2022. The regions covered in gastroparesis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastroparesis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The gastroparesis market consists of sales of metoclopramide, domperidone, and erythromycin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The gastroparesis research report is one of a series of new reports from The Business Research Company that provides gastroparesis market statistics, including the gastroparesis industry's global market size, regional shares, competitors with gastroparesis market share, detailed gastroparesis market segments, market trends and opportunities, and any further data you may need to thrive in the gastroparesis industry. This gastroparesis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.